patients were treated with Roche medicines in 2024
Roche Diagnostics test were delivered to customers worldwide in 2024
Core investments in research and development in 2024: CHF 13.2 billion
Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.
Roche has published its First Quarter Sales for 2025 prior to the opening of the Swiss Stock Exchange on Thursday, 24th April 2025.
Discover how we're revolutionalising patient care in our 2024 Annual Report. Focused on innovation, research, sustainability, and strategic partnerships, with insights into our groundbreaking approaches.
Do you need to get in touch with us? Reach out to our media team with your enquiries.
